Yuee Teng

机构：Henan Academy of Agricultural Sciences, First Hospital of China Medical University, China Medical University · ORCID：0000-0002-9198-9795

发表论文 118 篇 · 总被引 2418 次 · h-index 28

代表论文

• Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 120)
• Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial (2023 · BMJ · 被引 87)
• Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021 (2023 · JAMA Network Open · 被引 32)
• Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial (2023 · BMC Medicine · 被引 20)
• PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer (2025 · Cell Death and Disease · 被引 9)
• Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 8)